We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Expanded Access Program for Rexin-G™ Provides Genetic Medicine to Cancer Patients
News

Expanded Access Program for Rexin-G™ Provides Genetic Medicine to Cancer Patients

Expanded Access Program for Rexin-G™ Provides Genetic Medicine to Cancer Patients
News

Expanded Access Program for Rexin-G™ Provides Genetic Medicine to Cancer Patients

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Expanded Access Program for Rexin-G™ Provides Genetic Medicine to Cancer Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epeius Biotechnologies Corporation has announced that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G™, the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer.

Following the landmark approval of Rexin-G™ for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila.

In a statement to the press, Dr. Erlinda Maria Gordon, M.D., Chairman, added, "We are pleased that the value of Rexin-G™ in the management of cancer is being appreciated by the international medical community, and that patients who are refractory to conventional chemotherapy now have additional options."

Ideally suited, by design, to function within the context of the human circulatory system, Rexin-G™ represents the first in a series of truly effective targeted genetic medicines that seek out and destroy metastatic cancer, without eliciting deleterious side effects or organ damage.

The unique Targeted Delivery System (TDS technology) engineered into Rexin-G™ carries a tumor-killing designer gene selectively to diseased tissues with such precision that a new term - "Pathotropic (or disease- seeking) Medicine" - was required to describe its properties.

Rexin-G™ recently gained FDA Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials at several American institutions, including Mayo Clinic in Minnesota.

Advertisement